Sign inJoin waitlistJoin the waitlist

Moshe Ornstein

Physician · Cleveland Clinic

Credentials: · · · · ·

History

Cleveland Clinic
Present

Cleveland Clinic
2015–2017
Cleveland Clinic
2011–2014
Columbia University
Renaissance School of Medicine at Stony Brook University
2007–2011
Touro College
2001–2005

Research

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Journal for ImmunoTherapy of Cancer · 2018 · 160 citations
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Journal of Clinical Oncology · 2022 · 88 citations
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study
The Lancet Oncology · 2019 · First of 15 authors · Corresponding · 84 citations

Brian Rini
41 papers
Timothy Gilligan
32 papers
Jorge Garcia
29 papers
Petros Grivas
19 papers
IS
Iris Sheng
9 papers · 7 as a fellow
Shilpa Gupta
9 papers
AS
Andrew Stephenson
8 papers
Steven Campbell
8 papers
Vadim Koshkin
8 papers · 8 as a fellow
Amanda Nizam
7 papers · 7 as a fellow
Georges-Pascal Haber
7 papers
Byron Lee
6 papers

Clinical trials

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Principal investigator · Terminated · Phase 2
Case Comprehensive Cancer Center
2020–2023
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Principal investigator · Completed · Phase 2
Case Comprehensive Cancer Center
2017–2023
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Principal investigator · Completed · Phase 1
Moshe Ornstein
2016–2020
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
Principal investigator · Completed · Phase 2
Case Comprehensive Cancer Center
2016–2020